Carisma Therapeutics, On June 26, 2024, In Furtherance Of Its Revised Operating Plan, Notified Novartis Of Its Termination Of Manufacturing And Supply Agreement

Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, relating to the manufacture of the first product candidate to enter clinical development, CT-0508.

The termination is effective July 31, 2024. Pursuant to the Company’s revised operating plan, the Company determined to focus its ex vivo oncology clinical development efforts on its follow-on product candidate CT-0525 and has suspended enrollment of new patients in its Phase 1 clinical trial for CT-0508.

As a result of the termination of the Manufacturing Agreement, the Company will incur a termination fee equal to $4.0 million, which is expected to be paid in the third quarter of 2024.